Evaluation of diagnostic accuracy of DNA methylation biomarkers for bladder cancer: a systematic review and meta-analysis

References

• Bornman DM, Mathew S, Alsruhe J, et al. (2001). Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 159:831–5
   PubMed Web of Science ®Google Scholar
• Cabello MJ, Grau L, Franco N, et al. (2011). Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn 13:29–40
   PubMed Web of Science ®Google Scholar
• Cairns P. (2007). Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 7:531–43
   PubMedGoogle Scholar
• Chan MW, Chan LW, Tang NL, et al. (2002). Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8:464–70
   PubMed Web of Science ®Google Scholar
• Chen PC, Tsai MH, Yip SK, et al. (2011). Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics 4:45
   PubMedGoogle Scholar
• Chihara Y, Kanai Y, Fujimoto H, et al. (2013). Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer 13:275
   PubMed Web of Science ®Google Scholar
• Chung W, Bondaruk J, Jelinek J, et al. (2011). Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 20:1483–91
   PubMed Web of Science ®Google Scholar
• Costa VL, Henrique R, Danielsen SA, et al. (2010). Three epigenetic biomarkers, GDF15, TMEFF2 and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 16:5842–51
   PubMed Web of Science ®Google Scholar
• Costa VL, Henrique R, Danielsen SA, et al. (2011). TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 6:1120–30
   PubMed Web of Science ®Google Scholar
• Dhawan D, Hamdy FC, Rehman I, et al. (2006). Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 209:336–43
   Google Scholar
• Dulaimi E, Uzzo RG, Greenberg RE, et al. (2004). Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10:1887–93
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Weisenberger DJ, Cheng JC, et al. (2004). Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 10:7457–65
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Straub B, Miller, K. (2002). DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 41:668–76
   PubMed Web of Science ®Google Scholar
• Heichman KA, Warren JD. (2012). DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 50:1707–21
   Google Scholar
• Higgins Jpt, Greens S. (2011). Cochrane handbook for systematic reviews of interventions version 5.1.0. The cochrane collaboration. Available from: www.cochrane-handbook.org [last accessed March 2011]
   Google Scholar
• Hoque MO, Begum S, Topaloglu O, et al. (2006). Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 98:996–1004
   PubMedGoogle Scholar
• Jiang Y, Zhang R, Zheng J, et al. (2012). Meta-analysis of 125 rheumatoid arthritis-related single nucleotide polymorphisms studied in the past two decades. PLoS One 7:e51571
   PubMed Web of Science ®Google Scholar
• Karnes RJ, Fernandez CA, Shuber AP. (2012). A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc 87:835–42
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim YJ. (2009). Epigenetic biomarkers in urothelial bladder cancer. Expert Rev Mol Diagn 9:259–69
   Google Scholar
• Lee JY, Joo HJ, Cho DS, et al. (2012). Prognostic significance of sub staging according to the depth of lamina propria invasion in primary t1 transitional cell carcinoma of the bladder. Korean J Urol 53:317–23
   PubMedGoogle Scholar
• Lee MG, Kim HY, Byun DS, et al. (2001). Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61:6688–92
   PubMed Web of Science ®Google Scholar
• Meng W, Huebner A, Shabsigh A, et al. (2012). Combined RASSF1A and RASSF2A promoter methylation analysis as diagnostic biomarker for bladder cancer. Mol Biol Int 2012:701814(1–8)
   Google Scholar
• Negraes PD, Favaro FP, Camargo JL, et al. (2008). DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer 8:238
   PubMedGoogle Scholar
• Patchsung M, Boonla C, Amnattrakul P, et al. (2012). Long interspersed nuclear element-1 hypomethylation and oxidative stress: correlation and bladder cancer diagnostic potential. PLoS One 7:e37009
   PubMedGoogle Scholar
• Reinert T, Borre M, Christiansen A, et al. (2012). Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM and ZNF154 hypermethylation. PLoS One 7:e46297
   PubMed Web of Science ®Google Scholar
• Reinert T, Modin C, Castano FM, et al. (2011). Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 17:5582–92
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin 63:11–30
   PubMed Web of Science ®Google Scholar
• Sugano K, Kakizoe T. (2006). Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nat Clin Pract Urol 3:642–52
   PubMedGoogle Scholar
• Sun J, Chen Z, Zhu T, et al. (2009). Hypermethylated SFRP1, but none of other nine genes “informative” for western countries, is valuable for bladder cancer detection in Mainland China. J Cancer Res Clin Oncol 135:1717–27
   PubMedGoogle Scholar
• Thorlund K, Imberger G, Johnston BC, et al. (2012). Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One 7:e39471
   PubMed Web of Science ®Google Scholar
• Urakami S, Shiina H, Enokida H, et al. (2006). Combination analysis of hypermethylated wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 12:2109–16
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW, Burger M, Lotan Y, et al. (2009). Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430–42
   PubMed Web of Science ®Google Scholar
• Vinci S, Giannarini G, Selli C, et al. (2011). Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urol Oncol 29:150–6
   Google Scholar
• Wolff EM, Liang G, Cortez CC, et al. (2008). RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res 68:6208–14
   Google Scholar
• Yates DR, Rehman I, Abbod MF, et al. (2007). Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 13:2046–53
   PubMed Web of Science ®Google Scholar
• Yates DR, Rehman I, Meuth M, et al. (2006). Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 25:1984–8
   PubMed Web of Science ®Google Scholar
• Yu J, Zhu T, Wang Z, et al. (2007). A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13:7296–304
   PubMed Web of Science ®Google Scholar
• Zhao Y, Guo S, Sun J, et al. (2012). Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One 7:e35175
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Germenis AE. (2006). Performance of antibodies against tissue transglutaminase for the diagnosis of celiac disease: meta-analysis. Clin Vaccine Immunol 13:187–92
   PubMed Web of Science ®Google Scholar